 |
인쇄하기
취소
|
Samsung to invest 300 billion won in biosimilars business
Samsung Group said Friday it plans to set up a biopharmaceutical joint venture with Quintiles Transnational Corp., a U.S. drugmaker based in North Carolina.
The company said the joint venture will be established during the first half of this year, to be capitalized at 300 billion won ($265.5 million).
Samsung Group will have a 90-percent stake in the joint venture, with 40 percent being o...
The company said the joint venture will be established during the first half of this year, to be capitalized at 300 billion won ($265.5 million).
Samsung Group will have a 90-percent stake in the joint venture, with 40 percent being o...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.